Previous 10 | Next 10 |
2023-07-05 09:41:27 ET Cassava Sciences ( NASDAQ: SAVA ) announced Wednesday that its lead candidate simufilam slowed cognitive decline by 38% compared to placebo in a small proof-of-concept study for patients with mild-to-moderate Alzheimer’s disease. The U.S.-based tr...
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Months. In Mild...
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease. Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect. Research is Published in Frontiers in Aging , a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2023 (GLO...
NEW ORLEANS, June 24, 2023 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Cassava Sciences, Inc. (NasdaqCM: SAVA). Beginn...
2023-06-20 07:27:39 ET Summary Cassava Sciences' results from the 6-month randomized CMS, using simufilam for the treatment of mild-to-moderate AD patients, are expected to be released in Q3 of 2023. It is expected that the global Alzheimer's Disease market could reach $6.3 billio...
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research , a Peer-Reviewed Journal. AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences...
2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...
2023-06-08 14:30:41 ET If you’re like most traders in the stock market today, penny stocks are something to get familiar with. Now, keep in mind, I say “traders” and not “investors” for a reason. In many cases, these cheap stocks fluctuate rapidly in p...
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City. ...
2023-05-23 17:06:29 ET Summary Cassava stock - incredibly volatile between 2020-2022 - hasn't increased much in value in the last year. The company's Alzheimer's candidate Simufilam remains in Phase 3 studies with data likely arriving in 2024. The company remains heavily short...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...